🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to researchers.

An International Challenge

Gonorrhoea infections are increasing globally, with data suggesting in excess of 82 million new cases per year. Especially elevated rates are reported in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Health officials are deeply concerned about the rise in drug-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Receive Approval

One new antibiotic, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Results and Global Access

Based on findings published in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which involves a dual-drug approach. The research included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors directly involved have expressed hope. Access to a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is considered vital to reduce the burden of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea globally.